Skip to main content
Erschienen in: Current Hematologic Malignancy Reports 6/2018

18.10.2018 | Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN—Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community

verfasst von: Naveen Pemmaraju, Audun Utengen, Vikas Gupta, Michael A. Thompson, Andrew A. Lane

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Engagement on social media for professional, healthcare-related communication is rapidly rising around the world. We aimed to better understand the dynamics of a rare disease Twitter hashtag community.

Recent Findings

Twitter has served as a platform for academic discussion, a method for knowledge dissemination directly from medical meetings, and a venue for patient caregiver and support groups. One example of a rare cancer that has seen an increase in available information via Twitter is blastic plasmacytoid dendritic cell neoplasm, or BPDCN. This field has recently experienced a new wave of interest from various healthcare stakeholders in light of key new scientific breakthroughs and novel clinical trials now starting to be available.

Summary

In order to bring all relevant healthcare stakeholders together, the investigators of this article created a disease-specific Twitter community: #BPDCN = “blastic plasmacytoid dendritic cell neoplasm on social media” which has led to higher levels of engagement and discussion in the field. This article focuses on our analysis of advanced Twitter user-metrics in the second year of #BPDCN and discusses future directions for this rare cancer online disease community.
Literatur
1.
Zurück zum Zitat Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.CrossRef Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.CrossRef
2.
Zurück zum Zitat Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98:239–46.CrossRef Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98:239–46.CrossRef
3.
Zurück zum Zitat Guru Murthy GS, Pemmaraju N, Atallah E. Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. Leuk Res. 2018;73:21–3.CrossRef Guru Murthy GS, Pemmaraju N, Atallah E. Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. Leuk Res. 2018;73:21–3.CrossRef
4.
Zurück zum Zitat Alayed K, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013;88:1055–61.CrossRef Alayed K, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013;88:1055–61.CrossRef
5.
Zurück zum Zitat Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.CrossRef Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.CrossRef
6.
Zurück zum Zitat Deotare U, Yee KW, Le LW, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-color flow cytometry diagnosis and HyperCVAD therapy. Am J Hematol. 2016;91:283–6.CrossRef Deotare U, Yee KW, Le LW, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-color flow cytometry diagnosis and HyperCVAD therapy. Am J Hematol. 2016;91:283–6.CrossRef
7.
Zurück zum Zitat Swiecki M, Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol. 2015;15:471–85.CrossRef Swiecki M, Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol. 2015;15:471–85.CrossRef
8.
Zurück zum Zitat Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19:1006–12.CrossRef Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19:1006–12.CrossRef
9.
Zurück zum Zitat Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121:440–6.CrossRef Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121:440–6.CrossRef
10.
Zurück zum Zitat Pemmaraju N, Kantarjian, H. M., Khoury, J. D., O'Brien, S. M., Cortes, J. E., Garcia-Manero, G., Jabbour, E. J., Jain, N., Alvarado, Y., Duvic, M., Aung, P., Qazilbash, M. H., Yin, C. C., Konoplev, S. N., Patel, K. P., Pierce, S., Brandt, M., & Konopleva, M. Long-Term Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood 2017;130(Suppl 1). Pemmaraju N, Kantarjian, H. M., Khoury, J. D., O'Brien, S. M., Cortes, J. E., Garcia-Manero, G., Jabbour, E. J., Jain, N., Alvarado, Y., Duvic, M., Aung, P., Qazilbash, M. H., Yin, C. C., Konoplev, S. N., Patel, K. P., Pierce, S., Brandt, M., & Konopleva, M. Long-Term Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood 2017;130(Suppl 1).
11.
Zurück zum Zitat Aoki T, Suzuki R, Kuwatsuka Y, Kako S, Fujimoto K, Taguchi J, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2015;125:3559–62.CrossRef Aoki T, Suzuki R, Kuwatsuka Y, Kako S, Fujimoto K, Taguchi J, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2015;125:3559–62.CrossRef
12.
Zurück zum Zitat • Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol. 2016;14:220–2 This paper is a mini-review which can serve as a quick primer to introduce the medical /clinical topic of blastic plasmacytoid dendritic cell neoplasm.PubMed • Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol. 2016;14:220–2 This paper is a mini-review which can serve as a quick primer to introduce the medical /clinical topic of blastic plasmacytoid dendritic cell neoplasm.PubMed
13.
Zurück zum Zitat Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, et al. Blastic Plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to Venetoclax. Cancer discovery. 2017;7:156–64.CrossRef Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, et al. Blastic Plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to Venetoclax. Cancer discovery. 2017;7:156–64.CrossRef
14.
Zurück zum Zitat Pemmaraju N. Novel pathways and potential therapeutic strategies for Blastic Plasmacytoid dendritic cell neoplasm (BPDCN): CD123 and beyond. Curr Hematol Malig Rep. 2017;12:510–2.CrossRef Pemmaraju N. Novel pathways and potential therapeutic strategies for Blastic Plasmacytoid dendritic cell neoplasm (BPDCN): CD123 and beyond. Curr Hematol Malig Rep. 2017;12:510–2.CrossRef
15.
Zurück zum Zitat Pemmaraju N ea. RESULTS OF PIVOTAL PHASE 2 TRIAL OF SL-401 IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM. EHA 2018, Abstract #S116 2018. Pemmaraju N ea. RESULTS OF PIVOTAL PHASE 2 TRIAL OF SL-401 IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM. EHA 2018, Abstract #S116 2018.
16.
Zurück zum Zitat Pemmaraju N, Gupta V, Thompson MA, Lane AA. Social media and internet resources for patients with Blastic Plasmacytoid dendritic cell neoplasm (BPDCN). Curr Hematol Malig Rep. 2016;11:462–7.CrossRef Pemmaraju N, Gupta V, Thompson MA, Lane AA. Social media and internet resources for patients with Blastic Plasmacytoid dendritic cell neoplasm (BPDCN). Curr Hematol Malig Rep. 2016;11:462–7.CrossRef
17.
Zurück zum Zitat •• Thompson MA, Majhail NS, Wood WA, Perales MA, Chaboissier M. Social Media and the Practicing Hematologist: Twitter 101 for the Busy Healthcare Provider. Curr Hematol Malig Rep. 2015;10:405–12 This paper is a very practical, highly relevant primer on the basics of social media for professional use, aimed at the healthcare provider in a busy practice with limited time.CrossRef •• Thompson MA, Majhail NS, Wood WA, Perales MA, Chaboissier M. Social Media and the Practicing Hematologist: Twitter 101 for the Busy Healthcare Provider. Curr Hematol Malig Rep. 2015;10:405–12 This paper is a very practical, highly relevant primer on the basics of social media for professional use, aimed at the healthcare provider in a busy practice with limited time.CrossRef
18.
Zurück zum Zitat Thompson MA, Younes A, Miller RS. Using social media in oncology for education and patient engagement. Oncology (Williston Park). 2012;26:782 4–5, 91. Thompson MA, Younes A, Miller RS. Using social media in oncology for education and patient engagement. Oncology (Williston Park). 2012;26:782 4–5, 91.
19.
Zurück zum Zitat Thompson MA. Using social media to learn and communicate: it is not about the tweet. American Society of Clinical Oncology educational book / ASCO American Society of Clinical Oncology Meeting. 2015;35:206–11.CrossRef Thompson MA. Using social media to learn and communicate: it is not about the tweet. American Society of Clinical Oncology educational book / ASCO American Society of Clinical Oncology Meeting. 2015;35:206–11.CrossRef
21.
Zurück zum Zitat Pemmaraju N, Utengen A, Gupta V, Thompson MA, Lane AA. Analysis of first-year twitter metrics of a rare disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on social media: #BPDCN. Curr Hematol Malig Rep. 2017;12:592–7.CrossRef Pemmaraju N, Utengen A, Gupta V, Thompson MA, Lane AA. Analysis of first-year twitter metrics of a rare disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on social media: #BPDCN. Curr Hematol Malig Rep. 2017;12:592–7.CrossRef
22.
Zurück zum Zitat Katz MS, Utengen A, Anderson PF, Thompson, MA, Fisch M, Johnston C. Disease-specific hashtags for online communication about cancer care. J Clin Oncol 2015;33; suppl abstr 6520. Katz MS, Utengen A, Anderson PF, Thompson, MA, Fisch M, Johnston C. Disease-specific hashtags for online communication about cancer care. J Clin Oncol 2015;33; suppl abstr 6520.
23.
Zurück zum Zitat Pemmaraju N, Utengen A, Gupta V, Kiladjian JJ, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (MPN): analysis of advanced metrics from the first year of a new twitter community: #MPNSM. Curr Hematol Malig Rep. 2016;11:456–61.CrossRef Pemmaraju N, Utengen A, Gupta V, Kiladjian JJ, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (MPN): analysis of advanced metrics from the first year of a new twitter community: #MPNSM. Curr Hematol Malig Rep. 2016;11:456–61.CrossRef
24.
Zurück zum Zitat Patel SS, Majhail NS. Twitter use in the hematopoietic cell transplantation community. Curr Hematol Malig Rep. 2018;13:53–8.CrossRef Patel SS, Majhail NS. Twitter use in the hematopoietic cell transplantation community. Curr Hematol Malig Rep. 2018;13:53–8.CrossRef
25.
Zurück zum Zitat Gerds AT, Chan T. Social Media in Hematology in 2017: dystopia, utopia, or somewhere in-between? Curr Hematol Malig Rep. 2017;12:582–91.CrossRef Gerds AT, Chan T. Social Media in Hematology in 2017: dystopia, utopia, or somewhere in-between? Curr Hematol Malig Rep. 2017;12:582–91.CrossRef
26.
Zurück zum Zitat •• Pemmaraju N, Thompson MA, Mesa RA, Desai T. Analysis of the Use and Impact of Twitter During American Society of Clinical Oncology Annual Meetings From 2011 to 2016: Focus on Advanced Metrics and User Trends. Journal of oncology practice / American Society of Clinical Oncology. 2017;13:e623–e31 This original analyis describes the rise of Twitter use at one of the major medical meetings in all of medicine, the ASCO annual meeting and analyzes user metrics during these meetings over time.CrossRef •• Pemmaraju N, Thompson MA, Mesa RA, Desai T. Analysis of the Use and Impact of Twitter During American Society of Clinical Oncology Annual Meetings From 2011 to 2016: Focus on Advanced Metrics and User Trends. Journal of oncology practice / American Society of Clinical Oncology. 2017;13:e623–e31 This original analyis describes the rise of Twitter use at one of the major medical meetings in all of medicine, the ASCO annual meeting and analyzes user metrics during these meetings over time.CrossRef
27.
Zurück zum Zitat Logan AC. Using social Media at National Meetings in hematology-optimal use, tips, strategies, and limitations. Curr Hematol Malig Rep. 2017;12:605–10.CrossRef Logan AC. Using social Media at National Meetings in hematology-optimal use, tips, strategies, and limitations. Curr Hematol Malig Rep. 2017;12:605–10.CrossRef
28.
Zurück zum Zitat Pemmaraju N, Gupta V, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (MPN)-focus on twitter and the development of a disease-specific community: #MPNSM. Curr Hematol Malig Rep. 2015;10:413–20.CrossRef Pemmaraju N, Gupta V, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (MPN)-focus on twitter and the development of a disease-specific community: #MPNSM. Curr Hematol Malig Rep. 2015;10:413–20.CrossRef
Metadaten
Titel
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN—Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community
verfasst von
Naveen Pemmaraju
Audun Utengen
Vikas Gupta
Michael A. Thompson
Andrew A. Lane
Publikationsdatum
18.10.2018
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 6/2018
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-018-0490-6

Weitere Artikel der Ausgabe 6/2018

Current Hematologic Malignancy Reports 6/2018 Zur Ausgabe

Molecular Testing and Diagnostics (J Khoury, Section Editor)

Blastic Plasmacytoid Dendritic Cell Neoplasm

Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Online and Social Media Resources for Patients with MDS

CART and Immunotherapy (M Ruella, Section Editor)

Novel Immunotherapies for T Cell Lymphoma and Leukemia

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.